| 1.33 -0.04 (-2.92%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.75 | 1-year : | 2.04 |
| Resists | First : | 1.5 | Second : | 1.75 |
| Pivot price | 1.36  |
|||
| Supports | First : | 1.19 | Second : | 1 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.31 |
| MA(100) : | 1.65 |
MA(250) : | 4.02 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 60.8 |
D(3) : | 62.4 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 9.44 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MTEM ] has closed above bottom band by 22.9%. Bollinger Bands are 82.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.42 | 1.42 - 1.42 |
| Low: | 1.31 - 1.32 | 1.32 - 1.33 |
| Close: | 1.32 - 1.33 | 1.33 - 1.34 |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Fri, 12 Apr 2024
Molecular Templates Inc Announces Layoffs, CMO Resignation - TipRanks
Wed, 03 Apr 2024
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding - Simply Wall St
Tue, 19 Mar 2024
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Markets Insider
Mon, 04 Mar 2024
Molecular Templates, Inc. Provides Interim Update - GlobeNewswire
Mon, 13 Nov 2023
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update - BioSpace
Wed, 05 Apr 2023
9 Hot Penny Stocks Under $0.99 To Watch Right Now - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 57.7 (%) |
| Shares Short | 128 (K) |
| Shares Short P.Month | 200 (K) |
| EPS | -4.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.09 |
| Profit Margin | -58 % |
| Operating Margin | -0.5 % |
| Return on Assets (ttm) | -26.4 % |
| Return on Equity (ttm) | -929.2 % |
| Qtrly Rev. Growth | -69.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.82 |
| EBITDA (p.s.) | -2.49 |
| Qtrly Earnings Growth | -97.2 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.29 |
| PEG Ratio | -0.2 |
| Price to Book value | 1.22 |
| Price to Sales | 0.27 |
| Price to Cash Flow | -0.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|